Related Experiment Video
Updated: Mar 4, 2026
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases
Hua Zhu Ke1, William G Richards, Xiaodong Li
1Metabolic Disorders Research, Amgen Inc., One Amgen Center Drive, MS 29-M-B, Thousand Oaks, California 91320, USA. hke@amgen.com
Abstract:
The processes of bone growth, modeling, and remodeling determine the structure, mass, and biomechanical properties of the skeleton. Dysregulated bone resorption or bone formation may lead to metabolic bone diseases. The Wnt pathway plays an important role in bone formation and regeneration, and expression of two Wnt pathway inhibitors, sclerostin and Dickkopf-1 (DKK1), appears to be associated with changes in bone mass. Inactivation of sclerostin leads to substantially increased bone mass in humans and in genetically manipulated animals. Studies in various animal models of bone disease have shown that inhibition of sclerostin using a monoclonal antibody (Scl-Ab) increases bone formation, density, and strength. Additional studies show that Scl-Ab improves bone healing in models of bone repair. Inhibition of DKK1 by monoclonal antibody (DKK1-Ab) stimulates bone formation in younger animals and to a lesser extent in adult animals and enhances fracture healing. Thus, sclerostin and DKK1 are emerging as the leading new targets for anabolic therapies to treat bone diseases such as osteoporosis and for bone repair. Clinical trials are ongoing to evaluate the effects of Scl-Ab and DKK1-Ab in humans for the treatment of bone loss and for bone repair.
Insights
Inhibiting sclerostin and Dickkopf-1 (DKK1) promotes bone formation and strength. These Wnt pathway inhibitors are promising targets for treating osteoporosis and enhancing bone repair in clinical trials.
Area of Science:
- Bone biology and metabolic diseases
Background:
- Bone homeostasis relies on balanced resorption and formation, with dysregulation causing metabolic bone diseases.
- The Wnt signaling pathway is crucial for bone formation and regeneration.
- Sclerostin and Dickkopf-1 (DKK1) are key inhibitors of the Wnt pathway, influencing bone mass.
Purpose of the Study:
- To explore sclerostin and DKK1 as therapeutic targets for bone diseases and repair.
- To review the effects of inhibiting sclerostin and DKK1 on bone mass and healing.
Main Methods:
- Review of studies involving sclerostin monoclonal antibody (Scl-Ab) in animal models.
- Review of studies involving Dickkopf-1 monoclonal antibody (DKK1-Ab) in animal models.
Main Results:
- Sclerostin inactivation significantly increases bone mass in humans and animals.
- Scl-Ab treatment enhances bone formation, density, strength, and healing in animal models.
- DKK1-Ab treatment stimulates bone formation and fracture healing, particularly in younger animals.
Conclusions:
- Sclerostin and DKK1 are leading targets for anabolic therapies for osteoporosis and bone repair.
- Clinical trials are underway to assess Scl-Ab and DKK1-Ab efficacy in humans for bone loss and repair.
Related Concept Videos
01:40Bone Remodeling
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...